Ars pharmaceuticals has been granted approval by the us food and drug administration (fda) for their epinephrine nasal spray, neffy, to be used as treatment of type 1 allergic reactions including anaphylaxis.

Leading life science investor novo holdings has announced a £50m investment in oxford nanopore technologies. Oxford nanopore technologies is a leading uk-listed company currently specialising in a new generation of molecular sensing technology based on nanopores.

Drug discovery company Cresset has announced the extension of its global collaboration with chemical and biological contract research organisation (cro) Enamine.

Accord healthcare have recently announced that NICE have recommended the first oral androgen deprivation therapy (adt) treatment for hormone-sensitive prostate cancer. Prostate cancer is the most common cancer in men across the uk.

This month, Verisense have announced that their digital biobank, with data from over one million people, is open for business.

Biotechnology company Levicept has announced positive results from its phase 2 trial into levi-04 for the treatment of osteoarthritis.

Calliditas therapeutics ab has recently announced that the phase 2b transform trial met its primary endpoint. The trial showed statistically significant improvement in alkaline phosphatase (alp) for both doses tested versus placebo. the trial evaluated setanaxib, a nox enzyme inhibitor, in patients with primary biliary cholangitis (pbc) and elevated liver stiffness.

Merck (known as MSDoutside of the US and Canada) has announced that its anti-pd-1 therapy, in combination with padcev (enfortuman vedotin-ejfv), has received a positive opinion from the European Medicines Agency (EMA)

Researchers at the UCLA Health jonsson comprehensive cancer center have announced that they are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine. The vaccine targets h3 g34-mutant diffuse hemispheric glioma, an aggressive brain tumour typically found in adolescents and young people.

The National Institute for Health and Care excellence (NICE) have recommended adult patients in England or Wales with moderately or severely active ulcerative colitis (uc) who have not responded well to or cannot tolerate conventional or biological therapy including a tumour necrosis factor (tnf) alpha inhibitor the option of skyrizi (risankizumab).

This month, Janssen-Cilag international, part of johnson & johnson (j&j) has announced that the European Commission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (nsclc) with an epidermal growth factor receptor (EGFR).

Eisai and Econavista have announced that they have entered into a business alliance agreement, initiating their collaboration intended to build an ecosystem in the field of dementia.